Creo Medical Group PLC Annual Reports & Accounts & Notice of AGM (8288Y)
May 13 2019 - 5:50AM
UK Regulatory
TIDMCREO
RNS Number : 8288Y
Creo Medical Group PLC
13 May 2019
Creo Medical Group plc
("Creo" or "the Company")
Posting of Annual Reports and Accounts
Notice of Annual General Meeting
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
its Report and Accounts for the 18 month period ended 31 December
2018, together with its Notice of Annual General Meeting ("AGM")
and a Form of Proxy, will be mailed out to shareholders today.
These documents are available on the Company's website:
http://investors.creomedical.com/investors/reports-and-presentations/2019
The AGM will be held at 10 a.m. on Thursday 6 June 2019 at the
Company's registered office, Creo House, Unit 2, Beaufort Park,
Beaufort Park Way, Chepstow, Wales NP16 5UH.
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. Creo's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radio frequency energy (for precise localised
cutting) and microwave energy (for controlled coagulation). This
technology provides clinicians with flexible, accurate and
controlled surgical solutions.
Creo's strategy is to bring its CROMA Advanced Energy platform
to market through a suite of medical devices which Creo has
designed, initially for the emerging field of GI therapeutic
endoscopy, an area with high unmet needs. Creo intends to further
develop the CROMA Advanced Energy platform for use on flexible and
rigid endoscopic platforms for precise resection, dissection,
haemostasis and ablation. Creo believes its technology can impact
the landscape of surgery and endoscopy by providing a safer, less
invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEANSDFLXNEEF
(END) Dow Jones Newswires
May 13, 2019 05:50 ET (09:50 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Oct 2023 to Oct 2024